442 related articles for article (PubMed ID: 19041439)
1. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal study of lipids and blood pressure in relation to method of contraception in Latino women with prior gestational diabetes mellitus.
Xiang AH; Kawakubo M; Buchanan TA; Kjos SL
Diabetes Care; 2007 Aug; 30(8):1952-8. PubMed ID: 17519432
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and depot medroxyprogesterone acetate.
Albertazzi P; Bottazzi M; Steel SA
Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
[TBL] [Abstract][Full Text] [Related]
5. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
Westhoff C
J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
[TBL] [Abstract][Full Text] [Related]
7. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study.
Brito MB; Ferriani RA; Quintana SM; Yazlle ME; Silva de Sá MF; Vieira CS
Contraception; 2009 Dec; 80(6):519-26. PubMed ID: 19913145
[TBL] [Abstract][Full Text] [Related]
8. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
[TBL] [Abstract][Full Text] [Related]
9. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Arch Pediatr Adolesc Med; 2005 Feb; 159(2):139-44. PubMed ID: 15699307
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium.
Franceschini SA; Vieira CS; Martins WP; França JB; Ferriani RA
Contraception; 2013 Jun; 87(6):766-72. PubMed ID: 23102798
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
12. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Kaunitz AM
J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
Anwar M; Soejono SK; Maruo T; Abdullah N
Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate.
Dilshad H; Yousuf RI; Shoaib MH; Jamil S; Khatoon H
Am J Med Sci; 2016 Nov; 352(5):487-492. PubMed ID: 27865296
[TBL] [Abstract][Full Text] [Related]
15. Hormonal contraception and blood lead levels in inner-city adolescent girls.
Iglesias EA; Coupey SM; Markowitz ME
J Pediatr Adolesc Gynecol; 2008 Oct; 21(5):269-73. PubMed ID: 18794022
[TBL] [Abstract][Full Text] [Related]
16. Effects of the injectable contraceptive depot medroxyprogesterone acetate in Thai women with liver fluke infestation: final results.
Grossman RA; Asawasena W; Chalpati S; Taewtong D; Tovanabutra S
Bull World Health Organ; 1979; 57(5):829-37. PubMed ID: 161523
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormonal contraception on bone mineral density after 24 months of use.
Berenson AB; Breitkopf CR; Grady JJ; Rickert VI; Thomas A
Obstet Gynecol; 2004 May; 103(5 Pt 1):899-906. PubMed ID: 15121563
[TBL] [Abstract][Full Text] [Related]
19. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit.
Ishak R; Loh Chooi Khim
Malays J Reprod Health; 1991 Jun; 9(1):5-8. PubMed ID: 12317443
[TBL] [Abstract][Full Text] [Related]
20. Depot medroxyprogesterone acetate contraception in women with medical problems.
Frederiksen MC
J Reprod Med; 1996 May; 41(5 Suppl):414-8. PubMed ID: 8725704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
